Gyre Therapeutics' Q2 revenue misses estimates

Gyre Therapeutics

11/08/2025 21:14

Overview

Gyre Q2 revenue of $26.8 mln missed analyst expectations, per LSEG data

Net income for Q2 was $1.6 mln, compared to $4.5 mln last year

Company reaffirmed full-year revenue guidance of $118-128 mln

Ping Zhang appointed interim CEO as Dr. Han Ying transitions to scientific role

Outlook

Gyre reaffirms 2025 revenue guidance of $118-128 mln

Result Drivers

NEW PRODUCT LAUNCHES - Revenue increase driven by launch of Etorel and Contiva, contributing $1.6 mln and $1.5 mln respectively

ETUARY DECLINE - Sales of ETUARY decreased due to weaker economic conditions and increased competition in the IPF market

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$26.77 mln
$30.80 mln (1 Analyst)
Q2 Net Income
$1.58 mln
Q2 Operating Profit
$2.17 mln
Q2 Pretax Profit
$2.24 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Gyre Therapeutics Inc is $20.00, about 64.1% above its August 8 closing price of $7.19

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nGNXX3wJK

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)